PAML of Spokane, Washington, was the subject of an unusual public disclosure recently made by Laboratory Corporation of America. The lab company sent a statement to the Spokane Journal of Business stating its plans to make PAML “its primary lab site in the western U.S. for workplace and toxicology testing.” The statement was made to the newspaper by Donald R. Von Hagan, Labcorp’s Vice President of Communications. Civic and economic development leaders in Spokane have been concerned about LabCorp’s plans for PAML’s central laboratory facility that employs 800 FTEs in Spokane County.
MORE ON PAML
Along with the statement that LabCorp intended to use the PAML laboratory as its primary workplace and toxicology testing site for the western United States, Von Hagen stated that “Now that PAML is a LabCorp company, we remain committed to Spokane and the other communities that PAML and its joint ventures serve.”
SIX SIGMA GOAL ACHIEVED AT ARUP
At ARUP Laboratories in Salt Lake City, the semi-retired Charles Hawker, PhD, MBA, continues to achieve milestones in lab automation. In last month’s issue of the Journal of Applied Laboratory Medicine, Hawker and his colleagues wrote about their 25-year effort to achieve six sigma performance for lost specimens. ARUP handles 55,000 specimens daily and its use of automation with Lean and process improvement methods has helped it reduce the number of lost specimens to the six sigma rate of 3.4 defects per million events. Hawker believes ARUP is the first medical laboratory in the United States to document Six Sigma performance for a specific laboratory process.
• Haywood D. Cochrane Jr., was elected as Chairman of the University of North Carolina-Chapel Hill Board of Trustees. He is a graduate of the university and has held senior leadership positions at Midatech Pharma US, CHD Meridian Corporate Healthcare, Laboratory Corporation of America, Allied Clinical Laboratories, and Roche Biomedical Laboratories.
In a story about the acquisition of Med Fusion and ClearPoint Diagnostic Laboratories by Quest Diagnostics that was published by THE DARK REPORT on July 17, Quest did provide a statement after our publication deadline. Here is that statement:
“Med Fusion spearheaded a unique model for standardizing and simplifying precision medicine diagnostics in oncology. Assuming completion of the acquisition, the infusion of Quest’s resources, expertise and scale will allow our organizations to work together to further build this model and extend its reach to more physicians, particularly community oncologists, who deliver 70% of the nation’s cancer care. Our organizations’ shared commitment to innovation and quality provides a foundation from which to generate greater value for physicians and patients.”
That’s all the insider intelligence for this report.
Look for the next briefing on Monday, August 28, 2017.